ADEMEX and HEMO trials: where are we going?
Doubt has remained as to whether or not the K/DOQI recommended targets for adequacy of dialysis for peritoneal dialysis patients is appropriate (weekly Kt/V 2 + creatinine clearance 50-60 l/1.73 m(2)). The ADEMEX trial can be interpreted as indicating that lower targets might be acceptable. The HEMO trial, not yet published but presented in April 2002, casts doubts on the advantages of achieving higher than recommended small solute clearance targets. Taken together, these trials require that we broaden our concept of adequacy. There is also a risk of complacency with respect to dialysis adequacy because of these trials and this would be unwise.
Prichard
Sarah
S
Nephrology Division, Royal Victoria Hospital, McGill University Health Centre, Montreal, Que, Canada. sarah.prichard@muhc.mcgill.ca
D002985:Clinical Protocols / Q000592:standards; D006801:Humans; D018579:Patient Selection; D010530:Peritoneal Dialysis / Q000379:methods / Q000401:mortality / Q000592:standards*; D017410:Practice Guidelines as Topic; D016032:Randomized Controlled Trials as Topic / Q000379:methods / Q000401:mortality / Q000592:standards; D012107:Research Design